- Bayer last week announced the opening of its second-largest OTC drug manufacturing facility in the Asia-Pacific region. Located in Yunnan, China, the plant will produce OTC meds along with traditional Chinese medicines (TCM).
- The site was acquired by Bayer when it bought the Chinese pharmaceutical company Dihon in 2014.
- Bayer expects to have invested 1.4 billion yuan, or about $210 million, in the site by 2020.
Bayer has been investing in its manufacturing base in China. The German pharma giant has around 13,000 employees in China, along with several manufacturing and R&D facilities. It hopes to gain from China's burgeoning pharmaceutical market, which was expected to reach $63 billion in sales last year.
"[The facility] will boost our manufacturing capacity for TCM products by a factor of three in 2016, and will also triple the manufacturing and supplying capacity for all Dihon products by 2020," said Lance Yuen, Bayer Head of Greater China, in a statement.
The facility's initial production line for traditional Chinese medicines earned a good manufacturing practices (GMP) certification.
Recently, China has come under scrutiny for the quality of its drug manufacturing. The FDA has sent a number of warning letters to Chinese facilities manufacturing drugs for US markets, most recently to Zhejiang Hisun Pharmaceutical.